#1 Clinical Trials Search in Europe

Florbetapir (18F)

Florbetapir (18F), also known as Amyvid, is a radioactive diagnostic agent used in positron emission tomography (PET) imaging to detect beta-amyloid plaques in the brain. These plaques are associated with Alzheimer’s disease (AD). This article explores various clinical trials investigating the use of Florbetapir (18F) in improving diagnosis, patient management, and understanding of Alzheimer’s disease progression.

Table of Contents

What is Florbetapir (18F)?

Florbetapir (18F) is a diagnostic drug used in medical imaging. It’s also known by several other names, including Florbetapir F 18, Amyvid, 18F-AV-45, and AV-45[1][2]. This drug is not a treatment for Alzheimer’s disease, but rather a tool to help doctors diagnose the condition more accurately.

How Does Florbetapir (18F) Work?

Florbetapir (18F) works by binding to amyloid plaques in the brain. Amyloid plaques are abnormal clusters of protein that build up between nerve cells and are believed to play a role in Alzheimer’s disease. When Florbetapir (18F) is injected into the body, it travels to the brain and attaches to these plaques. Then, using a special type of scan called a Positron Emission Tomography (PET) scan, doctors can see where the Florbetapir (18F) has accumulated, showing them the location and amount of amyloid plaques in the brain[1].

Uses of Florbetapir (18F)

The primary use of Florbetapir (18F) is to help diagnose Alzheimer’s disease and related cognitive disorders. It’s particularly useful in the following situations:

  • Early detection: Florbetapir (18F) can help identify people who might be at risk for developing Alzheimer’s disease before they show any symptoms[2].
  • Differential diagnosis: It can help doctors distinguish Alzheimer’s disease from other types of dementia[3].
  • Research: Florbetapir (18F) is used in studies to better understand how Alzheimer’s disease progresses and to evaluate potential new treatments[3].

How is Florbetapir (18F) Administered?

Florbetapir (18F) is given as a single intravenous (IV) injection. The typical dose is about 370 megabecquerels (MBq) or 10 millicuries (mCi)[4]. After the injection, patients typically wait about 50-60 minutes before undergoing a PET scan that lasts about 10 minutes[2]. It’s important to note that patients don’t receive Florbetapir (18F) as a regular medication, but only as part of a specific diagnostic procedure.

Research Studies Using Florbetapir (18F)

Several research studies have been conducted to evaluate the effectiveness and applications of Florbetapir (18F). Some key areas of research include:

  • Improving diagnostic accuracy: Studies have looked at how Florbetapir (18F) PET scans can improve the accuracy of Alzheimer’s disease diagnosis[1].
  • Impact on patient management: Research has examined how the results of Florbetapir (18F) scans influence doctors’ decisions about patient care[2].
  • Predicting cognitive decline: Studies have investigated whether Florbetapir (18F) scan results can predict future cognitive decline in patients[2].
  • Standardization of measurements: Researchers have worked on standardizing how Florbetapir (18F) scan results are measured and interpreted across different medical centers[5].

Safety and Side Effects

Florbetapir (18F) is generally considered safe when used as directed. As with any medical procedure involving radiation, there is a small risk associated with the exposure. However, the amount of radiation used in a Florbetapir (18F) PET scan is relatively low[4].

It’s important to note that a Florbetapir (18F) scan is a diagnostic tool, not a treatment. A positive scan result doesn’t necessarily mean a person has Alzheimer’s disease, and a negative result doesn’t rule it out completely. The scan results should always be interpreted by a trained healthcare professional in conjunction with other clinical information.

Aspect Details
Primary Use Detection of beta-amyloid plaques in the brain using PET imaging
Clinical Trial Focus Areas Diagnostic accuracy, impact on patient management, relationship with cognitive decline, standardization of imaging interpretation
Key Findings Potential to change patient management, improve diagnostic confidence, predict cognitive decline in individuals with positive scans
Challenges Standardization of image interpretation, integration with other diagnostic tools, long-term prognostic value
Future Directions Longitudinal studies on amyloid load changes, integration with other biomarkers, use in preclinical Alzheimer’s disease research

FAQ

  • What is Florbetapir (18F) and how is it used? Florbetapir (18F) is a radioactive diagnostic agent used in PET imaging. It binds to beta-amyloid plaques in the brain, allowing doctors to visualize and assess the presence of these plaques, which are associated with Alzheimer's disease.
  • How can Florbetapir (18F) PET scans impact patient management? Clinical trials have shown that Florbetapir (18F) PET scans can lead to changes in patient management, including adjustments in diagnosis, medication, counseling, and follow-up care. This information can help doctors make more informed decisions about treatment and support for patients with cognitive impairment.
  • Are there any risks associated with Florbetapir (18F) PET scans? Florbetapir (18F) PET scans involve exposure to a small amount of radiation. However, the radiation dose is generally considered low and the benefits of the diagnostic information often outweigh the risks. Always discuss potential risks with your healthcare provider.
  • Can Florbetapir (18F) PET scans definitively diagnose Alzheimer's disease? While Florbetapir (18F) PET scans can detect beta-amyloid plaques associated with Alzheimer's disease, they cannot definitively diagnose AD on their own. The scans are used in conjunction with clinical evaluations and other tests to support diagnosis and guide patient management.
  • How might Florbetapir (18F) PET scans be useful in Alzheimer's disease research? Florbetapir (18F) PET scans are valuable in research for understanding the relationship between amyloid plaques and cognitive decline, evaluating the effectiveness of potential treatments, and studying the progression of Alzheimer's disease over time. They may also help identify individuals at risk for developing AD before symptoms appear.

Ongoing Clinical Trials on Florbetapir (18F)

  • A study testing trontinemab compared to placebo in patients with early Alzheimer’s disease including mild cognitive impairment and mild dementia

    Recruiting

    1 1 1
    Investigated drugs:
    Denmark France Germany Italy Poland Spain

  • Study of Trontinemab Compared to Placebo for Patients with Early Symptomatic Alzheimer’s Disease

    Recruiting

    1 1 1
    Investigated drugs:
    Denmark France Germany Italy The Netherlands Poland +1

  • Study of flortaucipir and florbetapir in patients with memory disorders including Alzheimer’s disease and dementia

    Not yet recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on the Effects of Sabirnetug for Patients with Early Alzheimer’s Disease

    Not yet recruiting

    1 1
    Investigated drugs:
    France Germany Spain

  • Study on Donanemab, Florbetapir, and Flortaucipir for Patients with Early Alzheimer’s Disease

    Not recruiting

    1
    Investigated diseases:
    Investigated drugs:
    Czechia The Netherlands Poland

  • A Study of Donanemab in People With Early Symptomatic Alzheimer’s Disease

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Poland Spain

  • Study on the Effectiveness and Safety of GSK4527226 in Patients with Early Alzheimer’s Disease

    Not recruiting

    1 1
    Investigated drugs:
    Finland France Germany Italy The Netherlands Norway +2

Glossary

  • Florbetapir (18F): A radioactive diagnostic agent used in PET imaging to detect beta-amyloid plaques in the brain, associated with Alzheimer's disease. Also known as Amyvid or 18F-AV-45.
  • Positron Emission Tomography (PET): An imaging technique that uses radioactive tracers to visualize and measure metabolic processes in the body, including the brain.
  • Beta-amyloid plaques: Abnormal clusters of protein fragments that build up between nerve cells in the brain, associated with Alzheimer's disease.
  • Alzheimer's Disease (AD): A progressive brain disorder that slowly destroys memory and thinking skills, eventually affecting the ability to carry out simple tasks.
  • Mild Cognitive Impairment (MCI): A condition characterized by a slight but noticeable decline in cognitive abilities, including memory and thinking skills. It may progress to dementia in some cases.
  • Standard Uptake Value ratio (SUVr): A measure used in PET imaging to quantify the uptake of a radiotracer in specific regions of interest compared to a reference region.
  • Centiloid scale: A standardized quantitative scale for amyloid PET imaging, allowing for comparison of results across different amyloid tracers and analysis methods.
  • ADAS-Cog: Alzheimer's Disease Assessment Scale-Cognitive Subscale, a test used to measure cognitive function in Alzheimer's disease clinical trials.
  • Biomarker: A measurable indicator of the presence or severity of a disease state, such as beta-amyloid plaques in Alzheimer's disease.
  • Preclinical Alzheimer's disease: A stage where individuals have brain changes associated with Alzheimer's disease but do not yet show symptoms of cognitive decline.

References

  1. https://clinicaltrials.gov/study/NCT02029547
  2. https://clinicaltrials.gov/study/NCT01703702
  3. https://clinicaltrials.gov/study/NCT02164643
  4. https://clinicaltrials.gov/study/NCT01660815
  5. https://clinicaltrials.gov/study/NCT02120664